July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
In vivo assessment of visual acuity following genipin-induced scleral crosslinking
Author Affiliations & Notes
  • Bailey Hannon
    Mechanical Engineering, Georgia Institute of Technology, ATLANTA, Georgia, United States
  • Jieming Fu
    Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Atlanta, Georgia, United States
  • A Thomas Read
    Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, United States
  • Machelle T Pardue
    Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Atlanta, Georgia, United States
    Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, United States
  • C Ross Ethier
    Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, United States
  • Footnotes
    Commercial Relationships   Bailey Hannon, None; Jieming Fu, None; A Read, None; Machelle Pardue, None; C Ethier, None
  • Footnotes
    Support  NIH EY025286
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2024. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Bailey Hannon, Jieming Fu, A Thomas Read, Machelle T Pardue, C Ross Ethier; In vivo assessment of visual acuity following genipin-induced scleral crosslinking. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2024.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Scleral stiffening has been proposed as a potential therapy for glaucoma. Several studies have evaluated the use of genipin, a natural collagen crosslinker, to stiffen the posterior sclera ex vivo. However, ocular administration of genipin has not yet been studied in vivo and its effects on visual and retinal function are still unknown. Thus, we aim to assess visual and retinal function in vivo following genipin-induced crosslinking of the posterior rat sclera.

Methods : Nine male, retired breeder (9-12 months old), Brown Norway rats were anesthetized and received retrobulbar injections of 15mM genipin unilaterally (concentration based on preliminary in vivo scleral stiffening data) and vehicle contralaterally. The injected volume was 100µl per eye, divided into two 50µl injections, one to the nasal quadrant and one to the temporal quadrant. Visual function was evaluated by spatial frequency thresholds from optomotor response experiments and retinal function by full-field flash electroretinography (ERG) at 0 (pre-injection), 1, 2, and 4 weeks post-injection.

Results : Data from vehicle and genipin-injected eyes were normalized to baseline (week 0) values for analysis. Spatial frequency thresholds of vehicle and genipin-injected eyes were not significantly different over the four weeks (Fig. 1; Two-Way repeated ANOVA, main effect of treatment: p=0.54, n=7). Additionally, ERG a- and b-wave responses were similar between the two groups of eyes over the four weeks (Fig. 2; Two-Way repeated ANOVA, main effect of treatment: a-wave amplitude, p=0.34 and implicit time (IT), p = 0.30; b-wave amp., p=0.53 and IT, p=0.97, n=7).

Conclusions : Our data suggest that retrobulbar injections of 15mM genipin (100µl) do not adversely affect visual or retinal function in rats for up to 4 weeks post-injection. These promising results support the safe in vivo use of genipin to modify scleral stiffness. To evaluate genipin-induced crosslinking as a potential therapy for glaucoma, future work will evaluate retinal histology following genipin injection and the persistence of genipin’s scleral stiffening effect.
Support: NIH EY025286.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Figure 1: Normalized spatial frequency results. (ANOVA, Injection type: p=0.54, mean ± SD, n=7).

Figure 1: Normalized spatial frequency results. (ANOVA, Injection type: p=0.54, mean ± SD, n=7).

 

Figure 2: Normalized ERG results from brightest flash intensity (2.1 log cd s/m2). (ANOVA, Injection type: a-wave amp., p=0.34 and IT, p=0.30; b-wave amp., p=0.53 and IT p=0.97, mean ± SD, n ≥ 7).

Figure 2: Normalized ERG results from brightest flash intensity (2.1 log cd s/m2). (ANOVA, Injection type: a-wave amp., p=0.34 and IT, p=0.30; b-wave amp., p=0.53 and IT p=0.97, mean ± SD, n ≥ 7).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×